Literature DB >> 33467742

Chronic Active Epstein-Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods.

Ayako Arai1,2.   

Abstract

Chronic active Epstein-Barr virus infection (CAEBV) is a disease where Epstein-Barr virus (EBV)-infected T- or NK-cells are activated and proliferate clonally. The symptoms of this dual-faced disease include systemic inflammation and multiple organ failures caused by the invasion of infected cells: inflammation and neoplasm. At present, the only effective treatment strategy to eradicate EBV-infected cells is allogeneic stem cell transplantation. Lately, the investigation into the disease's pathogenic mechanism and pathophysiology has been advancing. In this review, I will evaluate the new definition in the 2017 WHO classification, present the advancements in the study of CAEBV, and unfold the future direction.

Entities:  

Keywords:  EBV-positive T-cell lymphoma of childhood; WHO classification; cutaneous chronic active Epstein–Barr virus infection; systemic chronic active Epstein–Barr virus infection

Year:  2021        PMID: 33467742      PMCID: PMC7829705          DOI: 10.3390/microorganisms9010180

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  42 in total

1.  The immunological synapse of CTL contains a secretory domain and membrane bridges.

Authors:  J C Stinchcombe; G Bossi; S Booth; G M Griffiths
Journal:  Immunity       Date:  2001-11       Impact factor: 31.745

2.  Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.

Authors:  E Fischer; C Delibrias; M D Kazatchkine
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

3.  Elevated expression of activation-induced cytidine deaminase in T and NK cells from patients with chronic active Epstein-Barr virus infection.

Authors:  Motonobu Nakamura; Seiko Iwata; Hiroshi Kimura; Yoshiki Tokura
Journal:  Eur J Dermatol       Date:  2011 Sep-Oct       Impact factor: 3.328

4.  Diagnostic values for the viral load in peripheral blood mononuclear cells of patients with chronic active Epstein-Barr virus disease.

Authors:  Yoshinori Ito; Michio Suzuki; Jun-ichi Kawada; Hiroshi Kimura
Journal:  J Infect Chemother       Date:  2015-12-17       Impact factor: 2.211

5.  Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection.

Authors:  Keiko Nomura; Hirokazu Kanegane; Keisuke Otsubo; Hiroshi Wakiguchi; Yukihiro Noda; Yoshihito Kasahara; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2011-05-28       Impact factor: 2.490

6.  Acquisition of viral receptor by NK cells through immunological synapse.

Authors:  Julie Tabiasco; Alain Vercellone; Fabienne Meggetto; Denis Hudrisier; Pierre Brousset; Jean-Jacques Fournié
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

7.  Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.

Authors:  Lu Jiang; Zhao-Hui Gu; Zi-Xun Yan; Xia Zhao; Yin-Yin Xie; Zi-Guan Zhang; Chun-Ming Pan; Yuan Hu; Chang-Ping Cai; Ying Dong; Jin-Yan Huang; Li Wang; Yang Shen; Guoyu Meng; Jian-Feng Zhou; Jian-Da Hu; Jin-Fen Wang; Yuan-Hua Liu; Lin-Hua Yang; Feng Zhang; Jian-Min Wang; Zhao Wang; Zhi-Gang Peng; Fang-Yuan Chen; Zi-Min Sun; Hao Ding; Ju-Mei Shi; Jian Hou; Jin-Song Yan; Jing-Yi Shi; Lan Xu; Yang Li; Jing Lu; Zhong Zheng; Wen Xue; Wei-Li Zhao; Zhu Chen; Sai-Juan Chen
Journal:  Nat Genet       Date:  2015-07-20       Impact factor: 38.330

Review 8.  A novel mechanism for inflammation-associated carcinogenesis; an important role of activation-induced cytidine deaminase (AID) in mutation induction.

Authors:  Tsutomu Chiba; Hiroyuki Marusawa
Journal:  J Mol Med (Berl)       Date:  2009-10       Impact factor: 4.599

9.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.

Authors:  J F Jones; S Shurin; C Abramowsky; R R Tubbs; C G Sciotto; R Wahl; J Sands; D Gottman; B Z Katz; J Sklar
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

10.  P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases.

Authors:  Mayumi Yoshimori; Honami Takada; Ken-Ichi Imadome; Morito Kurata; Kouhei Yamamoto; Takatoshi Koyama; Norio Shimizu; Shigeyoshi Fujiwara; Osamu Miura; Ayako Arai
Journal:  Cancer Med       Date:  2015-07-08       Impact factor: 4.452

View more
  3 in total

1.  A rare B-cell type chronic active Epstein-Barr virus infection patient mimicking lymphoma on 18F-FDG PET/CT and literature review.

Authors:  Hao Jiao; Yongbai Zhang; Zhao Chen; Xueqi Chen; Yongkang Qiu; Wenpeng Huang; Lin Nong; Lei Kang
Journal:  Am J Nucl Med Mol Imaging       Date:  2022-08-20

Review 2.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

Review 3.  Anti-viral triterpenes: a review.

Authors:  Priya Darshani; Shreya Sen Sarma; Amit K Srivastava; Rinku Baishya; Deepak Kumar
Journal:  Phytochem Rev       Date:  2022-03-05       Impact factor: 7.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.